Persistence and Adherence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis in US Commercial Claims Databases

被引：0
|
作者：
Engmann, N. [1 ]
Yang, E. [1 ]
Fiore, D. [1 ]
Pardo, G. [2 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P065
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [1] Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in US commercial claims data
    Engmann, Natalie J.
    Sheinson, Danny
    Bawa, Komal
    Ng, Carmen D.
    Pardo, Gabriel
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (05): : 639 - 649
  • [2] Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis for up to 18 months in the us
    Engmann, N.
    Sheinson, D.
    Ng, C.
    Julian, L.
    Pardo, G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 544 - 545
  • [3] Real-world outcomes with ocrelizumab compared with other disease-modifying therapies in US commercial claims databases
    Engmann, Natalie J.
    Sheinson, Daniel
    Yang, Erru
    Fiore, Damian
    Alvarez, Enrique
    Nair, Kavita V.
    Vollmer, Timothy L.
    NEUROLOGY, 2020, 94 (15)
  • [4] Persistence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in the German NeuroTransData registry
    Braune, Stefan
    Dirks, Petra
    Colloud, Seya
    Davies, Evan
    Wang, Qing
    Heer, Yanic
    Zurcher, Mel
    Sun, Diana
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 631 - 632
  • [5] Persistence and adherence of fingolimod compared with other disease modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis
    Bergvall, N.
    Lahoz, R.
    Agashivala, N.
    Pradhan, A.
    Capkun-Niggli, G.
    Korn, J. R.
    Petrilla, A. A.
    Karkare, S. U.
    McGuiness, C. Balderston
    Makin, C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 520 - 521
  • [6] Adherence and Persistence to Disease-Modifying Therapies for Multiple Sclerosis and Their Impact on Clinical and Economic Outcomes in a US Claims Database
    Pineda, Elmor
    Ng, Carmen
    Sheinson, Daniel
    Bonine, Nicole
    Pardo, Gabriel
    NEUROLOGY, 2021, 96 (15)
  • [7] Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
    Zanga, Gisela
    Drzewiscki, Estefania
    Tagliani, Paula
    Smietniansky, Maximiliano
    Rojas, Maria M. Esnaola y
    Caruso, Diego
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [8] Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
    Edward E. Neuberger
    Ibrahim M. Abbass
    Eddie Jones
    Natalie J. Engmann
    Neurology and Therapy, 2021, 10 : 183 - 196
  • [9] Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis
    Neuberger, Edward E.
    Abbass, Ibrahim M.
    Jones, Eddie
    Engmann, Natalie J.
    NEUROLOGY AND THERAPY, 2021, 10 (01) : 183 - 196
  • [10] Adherence, persistence and switching patterns of patients initiating ocrelizumab compared to other disease-modifying therapies in the real world
    Engmann, Natalie J.
    Yang, Erru
    Fiore, Damian
    Pardo, Gabriel
    NEUROLOGY, 2020, 94 (15)
12345